POSACONAZOLE vs VORICONAZOLE

Compare POSACONAZOLE (posaconazole) and VORICONAZOLE (VFEND) — clinical data, side effects, and patient experiences.

POSACONAZOLE

posaconazole · Antifungal

How it works

12.1 Mechanism of Action Posaconazole is an azole antifungal agent [ see Clinical Pharmacology (12.4) ].

Approved for

See full prescribing information

OralTablet

VORICONAZOLE

VFEND · Antifungal

How it works

12.1 Mechanism of Action Voriconazole is an antifungal drug [see Microbiology (12.4) ].

Approved for

in patients intolerant of

or refractory to

other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials

kidney

IntravenousTablet

Quick Comparison

POSACONAZOLEVORICONAZOLE

Drug Class

Antifungal

Route

Oral

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

POSACONAZOLE

Drug Not Working

>10%

Fever

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

Condition Worsened

0.1-1%

VORICONAZOLE

Drug Not Working

>10%

Fever

1-10%

Condition Worsened

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

Shortness of Breath

0.1-1%

FDA Warnings

POSACONAZOLE

5 WARNINGS AND PRECAUTIONS Calcineurin-Inhibitor Toxicity : Posaconazole increases concentrations of cyclosporine or tacrolimus; reduce dose of cyclosporine and tacrolimus and monitor concentrations frequently
5 ) Vincristine Toxicity : Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions; reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options
10 ) Venetoclax Toxicity : Concomitant administration of posaconazole with venetoclax may increase venetoclax toxicities, including the risk of tumor lysis syndrome, neutropenia, and serious infections; monitor for toxicity and reduce venetoclax dose
Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy studies in patients with elevated cyclosporine or tacrolimus concentrations

VORICONAZOLE

5 WARNINGS AND PRECAUTIONS • Hepatic Toxicity : Serious hepatic reactions reported
5 ) • Photosensitivity : Avoid sunlight due to risk of photosensitivity ( 5
1 Hepatic Toxicity In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with VFEND (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities)
Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly hematological malignancy)

Clinical Trial Data

No head-to-head clinical studies found for POSACONAZOLE vs VORICONAZOLE.

POSACONAZOLE vs VORICONAZOLE: What You Should Know

Key Differences

Both POSACONAZOLE and VORICONAZOLE belong to the Antifungal class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. POSACONAZOLE is administered via Oral, whereas VORICONAZOLE uses Intravenous. Route of administration can affect onset of action and patient adherence.

Safety Considerations

POSACONAZOLE carries 4 FDA warnings. VORICONAZOLE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

KETOCONAZOLE vs VORICONAZOLE→KETOCONAZOLE vs POSACONAZOLE→NYSTATIN vs VORICONAZOLE→NYSTATIN vs POSACONAZOLE→FLUCYTOSINE vs VORICONAZOLE→FLUCYTOSINE vs POSACONAZOLE→

Loading comparison data...

POSACONAZOLE vs VORICONAZOLE

Compare POSACONAZOLE (posaconazole) and VORICONAZOLE (VFEND) — clinical data, side effects, and patient experiences.

POSACONAZOLE

posaconazole · Antifungal

How it works

12.1 Mechanism of Action Posaconazole is an azole antifungal agent [ see Clinical Pharmacology (12.4) ].

Approved for

See full prescribing information

OralTablet

VORICONAZOLE

VFEND · Antifungal

How it works

12.1 Mechanism of Action Voriconazole is an antifungal drug [see Microbiology (12.4) ].

Approved for

in patients intolerant of

or refractory to

other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials

kidney

IntravenousTablet

Quick Comparison

POSACONAZOLEVORICONAZOLE

Drug Class

Antifungal

Route

Oral

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

POSACONAZOLE

Drug Not Working

>10%

Fever

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

Condition Worsened

0.1-1%

VORICONAZOLE

Drug Not Working

>10%

Fever

1-10%

Condition Worsened

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

Shortness of Breath

0.1-1%

FDA Warnings

POSACONAZOLE

5 WARNINGS AND PRECAUTIONS Calcineurin-Inhibitor Toxicity : Posaconazole increases concentrations of cyclosporine or tacrolimus; reduce dose of cyclosporine and tacrolimus and monitor concentrations frequently
5 ) Vincristine Toxicity : Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions; reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options
10 ) Venetoclax Toxicity : Concomitant administration of posaconazole with venetoclax may increase venetoclax toxicities, including the risk of tumor lysis syndrome, neutropenia, and serious infections; monitor for toxicity and reduce venetoclax dose
Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy studies in patients with elevated cyclosporine or tacrolimus concentrations

VORICONAZOLE

5 WARNINGS AND PRECAUTIONS • Hepatic Toxicity : Serious hepatic reactions reported
5 ) • Photosensitivity : Avoid sunlight due to risk of photosensitivity ( 5
1 Hepatic Toxicity In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with VFEND (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities)
Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly hematological malignancy)

Clinical Trial Data

No head-to-head clinical studies found for POSACONAZOLE vs VORICONAZOLE.

POSACONAZOLE vs VORICONAZOLE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.